NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ... [Yahoo! Finance]
NovoCure Limited - Ordinary Shares (NVCR)
Last novocure limited - ordinary shares earnings: 4/30 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
novocure.com/investor-relations
Company Research
Source: Yahoo! Finance
Gross Margin (Q4 2024): Gross Margin (Full Year 2024): 77%, up from 75% in 2023. Sales and Marketing Expenses (Q4 2024): $67 million. Sales and Marketing Expenses (Full Year 2024): $239 million. G&A Expenses (Q4 2024): $72 million. G&A Expenses (Full Year 2024): $190 million. R&D Expenses (Q4 2024): $51 million. R&D Expenses (Full Year 2024): $210 million. Net Loss (Q4 2024): $66 million or $0.61 per share. Net Loss (Full Year 2024): $169 million or $1.56 per share. Adjusted EBITDA (Q4 2024): $3 million, an increase of $34 million from Q4 2023. Adjusted EBITDA (Full Year 2024): $1 million, an increase of $107 million compared to last year. Cash and Cash Equivalents (End of 2024): $960 million. Warning! GuruFocus has detected 4 Warning Signs
Read more
Impact Snapshot
Event Time:
NVCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVCR alerts
High impacting NovoCure Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NVCR
News
- NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Novocure to Participate in Leerink Partners 2025 Global Healthcare ConferenceBusiness Wire
- NovoCure Limited (NASDAQ: NVCR) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- https://seekingalpha.com/article/4763298-novocures-expansion-strategy-struggles-to-translate-approvals-into-growth [Seeking Alpha]Seeking Alpha
- NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say [Yahoo! Finance]Yahoo! Finance
NVCR
Earnings
- 2/27/25 - Miss
NVCR
Sec Filings
- 3/6/25 - Form 4
- 3/6/25 - Form 4
- 3/6/25 - Form 4
- NVCR's page on the SEC website